Our Roadmap
Join us on a mission to transform cancer screening. TOBY is building a platform designed to detect multiple cancers early, using a single, simple urine sample. While our long-term vision is to expand across cancer types, we recognize that groundbreaking change starts with focused, decisive steps.
Explore our development journey and see how we’re shaping the future of early detection.
Performance
AUC, or “Area Under the Curve,” is one of the most important ways to evaluate how well a diagnostic model performs. It measures how accurately a test can distinguish between positive and negative cases, such as cancer and no cancer.
AUC values range from 0.5 to 1.0:
- AUC = 0.5 means the test performs no better than random chance
- AUC = 1.0 means the test is perfect
Diagnostic tests are typically rated as follows:
- Below 0.8 is considered poor performance
- Above 0.8 is a strong test
- Above 0.9 is excellent
Improving performance becomes more difficult at the high end of the scale, but the payoff is critical. That is why TOBY is being built to meet the highest bar. Our goal is to consistently deliver AUCs above 0.9, ensuring excellent performance in early cancer detection.
This is how early detection gets built
How We Build a Diagnostic Model
1. Academic Research
Assess scientific evidence supporting detection for a new disease
2. Internal Validation
Prototype and train a new algorithm using urine samples
3. Clinical Validation
Run a blinded study to confirm diagnostic accuracy
Tested in real-world settings to prove clinical accuracy
3. Clinical Validation
Data access reserved for investors
Proven in the lab. Optimized for accuracy.
2. Internal Validation
Breast Cancer
Global Cancer Incidence: 12.5%
Our Test AUC: Excellent
Mamogram Test: AUC = 0.78
Lung Cancer
Global Cancer Incidence: 12.2%
Our Test AUC: Excellent
LDCT Scan Test: AUC = 0.85
Colorectal Cancer
Global Cancer Incidence: 10.7%
Our Test AUC: Excellent
FIT Test: AUC = 0.92
Prostate Cancer
Global Cancer Incidence: 7.8%
Our Test AUC = Excellent
PSA Test: AUC = 0.68
Stomach Cancer
Global Cancer Incidence: 6.0%
Our Test AUC: Excellent
Competitor Test: None
Pancreatic Cancer
Global Cancer Incidence: 2.7%
Our Test AUC: Excellent
Competitor Test: None
Cervical Cancer
Global Cancer Incidence: 3.3%
Our Test AUC: Excellent
hrHPV Test: AUC = 0.74
Bladder Cancer
Global Cancer Incidence: 3.2%
Our Test AUC = Excellent
Competitor Test: None
Kidney Cancer
Global Cancer Incidence: 2.4%
Our Test AUC: Excellent
Competitor Test: None
Ovarian Cancer
Global Cancer Incidence: 1.7%
Our Test AUC: Excellent
Competitor Test: None
Grounded in evidence. Guided by the data.
1. Academic Research
Liver Cancer
Global Cancer Incidence: 5.0%
Indicative Research: AUC = 0.96
AFP Test: AUC = 0.94
Esophageal Cancer
Global Cancer Incidence: 3.3%
Indicative Research: AUC = 0.86
Competitor Test: None
Lymphoma
Global Cancer Incidence: 3.0%
Indicative Research: AUC = 0.82
Competitor Test: None
Endometrial Cancer
Global Cancer Incidence: 2.3%
Indicative Research: AUC = 0.81
Competitor Test: None
Brain & CNS Cancer
Global Cancer Incidence: 1.7%
Indicative Research: AUC = 0.85
Competitor Test: None